Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 12/20 | 0.61 |
| ▸ | ABCC4 | O15439 | 4/20 | 0.61 |
| ▸ | VDR | P11473 | 1/20 | 0.61 |
| ▸ | SLC10A2 | Q12908 | 4/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.54 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.54 |
| ▸ | SLC10A1 | Q14973 | 5/20 | 0.50 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5667728 | 0.86 | GPBAR1 (0.59) | GPBAR1ABCC4VDRSLC10A2NR1H4 | |
| SCHEMBL15156946 | 0.83 | GPBAR1 (0.54) | GPBAR1VDRSLC10A2NR1H4EPHA2 | |
| SCHEMBL10932516 | 0.83 | GPBAR1 (0.54) | GPBAR1VDRSLC10A2NR1H4EPHA2 | |
| SCHEMBL935606 | 0.83 | GPBAR1 (0.54) | GPBAR1VDRSLC10A2NR1H4EPHA2 | |
| Taurolithocholic Acid SCHEMBL24001385 | 0.76 | GPBAR1 (1.00) | GPBAR1ABCC4VDRSLC10A2NR1H4 | |
| Taurolithocholic Acid SCHEMBL18762171 | 0.76 | GPBAR1 (1.00) | GPBAR1ABCC4VDRSLC10A2NR1H4 | |
| Taurolithocholic Acid SCHEMBL364160 | 0.76 | GPBAR1 (1.00) | GPBAR1ABCC4VDRSLC10A2NR1H4 | |
| Taurolithocholic Acid SCHEMBL17309133 | 0.76 | GPBAR1 (1.00) | GPBAR1ABCC4VDRSLC10A2NR1H4 | |
| Taurolithocholic Acid SCHEMBL22727921 | 0.76 | GPBAR1 (1.00) | GPBAR1ABCC4VDRSLC10A2NR1H4 | |
| Taurolithocholic Acid SCHEMBL20065899 | 0.76 | GPBAR1 (1.00) | GPBAR1ABCC4VDRSLC10A2NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084432-B2 | Administering oligonucleotide targeted to human ICAM-1 mRNA for therapy | ISIS PHARMACEUTICALS, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20050196443-A1 | Pulsatile release compositions and methods for enhanced intestinal drug absorption | ISIS PHARMACEUTICALS, INC. (US) | 2005-09-08 | — | — | US | disclosed |
| US-20040162259-A1 | Compositions and methods for treatment of pouchitis | ISIS PHARMACEUTICALS, INC. | 2004-08-19 | — | — | US | disclosed |
| EP-1080103-A4 | COMPOSITIONS AND METHODS FOR NON-PARENTERAL DELIVERY OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20030040497-A1 | Compositions and methods for non-parenteral delivery of oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2003-02-27 | — | — | US | disclosed |
| EP-1080103-A1 | COMPOSITIONS AND METHODS FOR NON-PARENTERAL DELIVERY OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999060012-A1 | COMPOSITIONS AND METHODS FOR NON-PARENTERAL DELIVERY OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1999-11-25 | — | — | WO | disclosed |